Skip To Content
Precision Medicine for Your Practice: Exploring Somatic Cancer Panel Testing-CNE is a Course

Precision Medicine for Your Practice: Exploring Somatic Cancer Panel Testing-CNE

Self-paced
0.5 credits

Enroll

Full course description

About this Course

Precision Medicine for Your Practice is a series of short (30 min), online modules covering specific topics in genomics and precision medicine. In this module, Exploring Somatic Cancer Panel Testing, participants will learn about large somatic cancer panels, which test for dozens or hundreds of variants that may be driving cancer growth and suggest therapeutics targeted to the variants that are identified. When should these panels be used? And which patients are good candidates? Learn about benefits, limitations, and challenges of using large somatic cancer panels using the five parts of this module: overview information via an animated video; practice cases to facilitate learning-by-doing; "dig deeper" for more in-depth topics; and logistics and additional resources for more detail.

CNE Disclosures

Activity Overview:

Precision Medicine for Your Practice: Exploring Somatic Cancer Panel Testing
Release Date: 
December 20, 2016 
Expiration Date: September 21, 2020

Objectives
Upon completion of this educational activity, the learner will be able to:

  • Identify the types of clinical information that can be gained from large somatic cancer panels.
  • Determine how large somatic cancer panel results could be applied to patient care.

Target Audience
This activity is designed to meet the educational needs of practicing advanced practice nurses, physicians and physician assistants who provide oncology care.

CNE Approval Statement
The Jackson Laboratory is co-providing this continuing nursing education activity with the American Medical Association and Scripps Translational Science Institute. This continuing nursing education activity was approved by the Northeast Multi-State Division (NE-MSD), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Claiming Your Credit
In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 2 out of 3 questions correctly and 4) complete the evaluation.   

Nurses are eligible for a maximum of .5 contact hours upon the completion of this activity.

Planning Committee

  • Emily Edelman, MS, CGC, The Jackson Laboratory
  • Therese Ingram, MA, The Jackson Laboratory
  • Sean McConnell, PhD, American Medical Association
  • Laura Nicholson, MD, PhD, Scripps Research Translational Institute
  • Kate Reed, MPH, ScM, CGC, The Jackson Laboratory
  • Linda Steinmark, MS, LGC, The Jackson Laboratory
  • Janet K. Williams, PhD, RN, FAAN, University of Iowa

Abdallah Elias, Jeanette McCarthy, Katherine Johansen Taber, James O’Leary, and Suzanna Schott were involved in planning a previous version of this program.

Faculty and Authors
  • Emily Edelman, MS, CGC, The Jackson Laboratory
  • Therese Ingram Nissen, MA, The Jackson Laboratory
  • Katie Johansen Taber, PhD, Counsyl
  • Laura Nicholson, MD, PhD, Scripps Translational Science Institute
  • Kate Reed, MPH, ScM, CGC, The Jackson Laboratory
  • Suzanna Schott, ScM, CGC, The Jackson Laboratory

Conflict of Interest Disclosure
Unless otherwise noted, the program planners and faculty do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this course.

The following disclosures are reported that could be perceived as a real or apparent conflict of interest in the education program:

Janet K. Williams, PhD, RN, FAAN, stockholder of Pfizer
Katie Johansen Taber, PhD, Counsyl

In her role as a planner, Dr. Williams recused herself from all deliberations relating to content related to the commercial entities with which she has a financial interest and is not responsible for reviewing for bias any related content. All educational material has been peer-reviewed by external reviewers to assess for bias.

In her role as a content author, Dr. Johansen Taber completed these contributions prior to her employment at Counsyl. This work has also been peer-reviewed by external reviewers to assess for bias.

References
Damodaran S, Berger MF, Roychowdhury S. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. Am Soc Clin Oncol Educ Book. 2015:e175-82. http://www.ncbi.nlm.nih.gov/pubmed/25993170

Gingras I, Sonnenblick A, de Azambuja E, et al. The current use and attitudes towards tumor genome sequencing in breast cancer. Sci Rep. 2016. 6:22517 http://www.ncbi.nlm.nih.gov/pubmed/26931736

Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014 May. 32(13):1317-23. http://www.ncbi.nlm.nih.gov/pubmed/24663044

Gray SW, Park ER, Najita J, et al. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med. 2016. 18(10):1011-9. http://www.ncbi.nlm.nih.gov/pubmed/26866579

Le Tourneau C, Kamal M, Tsimberidou AM, et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. J Natl Cancer Inst. 2015. 108(4). http://www.ncbi.nlm.nih.gov/pubmed/26598514

Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res. 2012. 22(11):2101-8. http://www.ncbi.nlm.nih.gov/pubmed/23019146

Marrone M, Filipski KK, Gillanders EM, Schully SD, Freedman AN. Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies. PLoS Curr. 2014. 6. http://www.ncbi.nlm.nih.gov/pubmed/24904755

National Comprehensive Cancer Center. Guidelines for Treatment of Cancer by Site.http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 2014. 94(2):129-37. http://www.ncbi.nlm.nih.gov/pubmed/24378644

Subbiah V, Kurzrock R. Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016. 2(6):719-20. http://www.ncbi.nlm.nih.gov/pubmed/27078832

Tannock IF, Hickman JA. Limits to Personalized Cancer Medicine. N Engl J Med. 2016. 375(13):1289-94. http://www.ncbi.nlm.nih.gov/pubmed/27682039

West HJ. No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data. JAMA Oncol. 2016. ;2(6):717-8. http://www.ncbi.nlm.nih.gov/pubmed/27078630

Hardware/software Requirements
Audio speakers or headphones
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher 


Should you have questions regarding the content of the activity, please email Kate Reed or call 207.288.6971.
Should you have technical questions, please email Therese Ingram.

Disclaimer
All information in Precision Medicine for Your Practice is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Precision Medicine for Your Practice. Reliance on any information in Precision Medicine for Your Practice is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Precision Medicine for Your Practice.

Sign up for this course today!

Enroll